Evidence map›Paper›PMID 41430035›Full record

ArticleInternational journal of hematology2026

Outcomes of allogeneic hematopoietic stem cell transplantation for acquired pure red cell aplasia.

Yuma Noguchi, Takehiko Mori, Yasushi Onishi, Yukinori Nakamura, Minoru Kanaya, Shinichi Ito, Kosei Matsue, Shingo Yano, Makoto Onizuka, Tetsuya Nishida and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yuma NoguchiHematology Department, Musashino Red Cross Hospital, Tokyo, Japan.
Takehiko MoriDepartment of Hematology, Institute of Science Tokyo (IST), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan. mori.hema@tmd.ac.jp.ORCID http://orcid.org/0000-0002-8176-4760
Yasushi OnishiDepartment of Hematology, Tohoku University Hospital, Sendai, Japan.
Yukinori NakamuraThird Department of Internal Medicine, Yamaguchi University Hospital, Yamaguchi, Japan.
Minoru KanayaHematology Department, Aiiku Hospital, Sapporo, Japan.
Shinichi ItoDepartment of Hematology, Hakodate Municipal Hospital, Hakodate, Japan.
Kosei MatsueDivision of Hematology/Oncology, Kameda Medical Center, Chiba, Japan.
Shingo YanoDivision of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan.
Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
Tetsuya NishidaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Seitaro TerakuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Aichi, Japan.
Satoshi YoshiharaDepartment of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan.
Takeshi MaedaDepartment of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Tatsuo IchinoheResearch Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Katsuto TakenakaDepartment of Hematology, Ehime University, Ehime, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired pure red cell aplasia (PRCA) affects only the red blood cell lineage and responds to immunosuppressive therapy. Few reports describe the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory PRCA. This study investigated the outcomes of allo-HSCT for PRCA using Japanese nationwide registry data. Eight patients aged 16 years or older who underwent allo-HSCT for acquired PRCA were analyzed. Median ages at diagnosis of PRCA and HSCT were 39.5 (range 19-68) and 47.5 (range 21-68) years, respectively. Stem cell sources and donors were bone marrow (related, n = 2; unrelated, n = 3), umbilical cord blood (n = 2), and peripheral blood stem cells (related, n = 1). All patients achieved neutrophil engraftment with a median time to engraftment of 21 days. Four patients died within 3 months after HSCT; the causes of death were acute myocardial infarction, thrombotic microangiopathy, capillary leak syndrome, and bacterial pneumonia. The remaining four patients were alive and transfusion-independent at a median follow-up of 99.4 months (range 21-148). Allo-HSCT could be a curative treatment option for refractory PRCA. However, early post-transplant mortality is an obstacle, and thus, optimal transplant procedures should be carefully determined for each patient.

Indexed as

Hematopoietic Stem Cell TransplantationRed-Cell Aplasia, PureAdultAgedFemaleHumansJapanMaleMiddle AgedTransplantation, HomologousTreatment OutcomeYoung AdultAcquired pure red cell aplasiaAllogeneic hematopoietic stem cell transplantationTransfusionTransplant-related mortality

Identifiers

PMID41430035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.